Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome.

Lindsay Rein,Karel Calero, Ronak Shah, Charles Ojielo,Kristin M Hudock, Saba Lodhi,Farid Sadaka,Shashi Bellam,Christopher Palma,David N Hager,Jeannie Daniel, Richard Schaub, Kevin O'Hayer,Nicole M Theodoropoulos

Critical care medicine（2022）

引用 13|浏览4

暂无评分

摘要

The observed reduction in 28-day mortality rate between ruxolitinib and placebo in mechanically ventilated patients with COVID-19-associated acute respiratory distress syndrome was not statistically significant; however, the trial was underpowered owing to early termination.

查看译文

关键词

COVID-19,Janus kinase inhibitors,randomized controlled trial,respiration,artificial,respiratory distress syndrome,severe acute respiratory syndrome coronavirus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要